
AstraZeneca Secures 2 FDA Approvals in Bladder Cancer, Myasthenia Gravis
Key Takeaways
- FDA cleared perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible/refusing MIBC: 3 neoadjuvant cycles of EV+durvalumab, then 9 adjuvant durvalumab cycles post-cystectomy.
- VOLGA interim results showed improved EFS (HR 0.51) and OS (HR 0.58) versus cystectomy with/without approved adjuvant therapy, with grade 3/4 AEs of 64% vs 44%.
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
The FDA approved 2 AstraZeneca biologics in the space of 4 days.1,2 On Nov. 13, 2026, the company announced US approval of Imfinzi (durvalumab) in a perioperative regimen with enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). On Nov. 16, Alexion, AstraZeneca Rare Disease, announced approval of Klygefa (gefurulimab) for generalized myasthenia gravis (gMG). One is an oncology combination regimen given around surgery and the other is a once-weekly self-injected rare disease therapy, so they place different demands on development and supply chains.
What Does the Durvalumab Approval Cover?
The FDA approved durvalumab with EV as neoadjuvant treatment, followed by durvalumab monotherapy as adjuvant treatment after radical cystectomy.1 The approval covers adults with MIBC who are ineligible for or have refused cisplatin-based chemotherapy, and it followed Priority Review. Approximately 16,000 patients will be treated for MIBC in the US in 2026. As many as 50% of patients are ineligible for cisplatin because of impaired renal function or comorbidities.
In the phase 3 VOLGA trial, patients received 3 cycles of durvalumab and EV before surgery, then 9 cycles of adjuvant durvalumab.1 At a planned interim analysis, the regimen reduced the risk of disease progression, recurrence, not undergoing surgery, or death by 49% compared with radical cystectomy with or without approved adjuvant treatment (event-free survival hazard ratio, 0.51; 95% CI, 0.38-0.67; P < .0001). It also reduced the risk of death by 42% (overall survival hazard ratio, 0.58; 95% CI, 0.40-0.83; P = .0027). Grade 3 and 4 adverse events from any cause occurred in 64% of patients receiving the combination and 44% of the comparator arm.
Jonathan Rosenberg, MD, chief of the Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, said in the press release,1 “This approval brings the first perioperative immunotherapy regimen where enfortumab vedotin is administered only in the neoadjuvant setting to patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy. The results of VOLGA show a statistically significant and clinically meaningful improvement in both event-free and overall survival along with a manageable safety profile. Based on this, the VOLGA regimen has the potential to become a new standard of care in this curative-intent setting.”
What Did the FDA Approve for Generalized Myasthenia Gravis?
Gefurulimab is approved for adults with gMG who are antiacetylcholine receptor (AChR) antibody-positive.2 It is the first and only dual-binding nanobody C5 inhibitor. Patients give it to themselves once a week as a subcutaneous injection with an autoinjector. An estimated 98,500 people in the US are diagnosed with gMG, and 81,000 of them are AChR-positive.
In the phase 3 PREVAIL trial, which enrolled 260 patients from 20 countries, gefurulimab improved the Myasthenia Gravis Activities of Daily Living total score from baseline at week 26 compared with placebo (treatment difference, –1.6; 95% CI, –2.4 to –0.8; P < .0001).2 Improvement was seen as early as week one. The most common treatment-emergent adverse events were injection site reactions (12%), back pain (8%), and vomiting (5%). The safety profile was consistent with earlier trials of eculizumab and ravulizumab in gMG.
Kelly Gwathmey, MD, associate professor in the Department of Neurology’s Division of Neuromuscular Medicine, Columbia University, said, in a press release,2 “gMG is a disease marked by unpredictability and variability, for which early intervention and reliable disease control are critical treatment goals. In the PREVAIL Phase 3 trial, gefurulimab achieved both, delivering rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection. With this approval, patients in the US gain a targeted treatment option that empowers greater autonomy with the established efficacy of C5 complement inhibition.”
Why Do These Approvals Matter?
The durvalumab decision adds a second checkpoint inhibitor–EV regimen to perioperative MIBC treatment.1 In July, the
Gefurulimab binds C5 and also binds serum albumin, which extends its half-life and makes weekly dosing possible.2 In October,
References
- AstraZeneca. Perioperative Imfinzi approved in the US in novel regimen with neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer. News release. November 13, 2026. Accessed November 16, 2026.
https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-ev-approve-in-us-in-bladder-cancer.html - AstraZeneca. Klygefa (gefurulimab) approved in the US for the treatment of generalised myasthenia gravis (gMG) in adult patients. News release. November 16, 2026. Accessed November 16, 2026.
https://www.astrazeneca.com/media-centre/press-releases/2026/klygefa-gefurulimab-approved-in-the-US.html - Zubulake Z. FDA activity round up – July 2026. Pharmaceutical Technology. July 15, 2026. Accessed November 16, 2026.
https://www.pharmtech.com/view/fda-activity-round-up-july-2026 - Zubulake Z. Ravulizumab’s IgA nephropathy approval expands large-molecule biologic demand. Pharmaceutical Technology. October 22, 2026. Accessed November 16, 2026.
https://www.pharmtech.com/view/ravulizumab-iga-nephropathy-approval-expands-large-molecule-biologic-demand
Related to this article









